Details for Patent: 11,844,784

Which drugs does patent 11,844,784 protect, and when does it expire?

Patent 11,844,784 protects VIVIMUSTA and is included in one NDA.

Summary for Patent: 11,844,784

Title:	Stable pharmaceutical compositions of bendamustine
Abstract:	Stable, injectable pharmaceutical compositions are provided, which are useful as ready-to-dilute (RTD) or ready-to-use (RTU) liquid injectable compositions comprising bendamustine or a pharmaceutically acceptable salt thereof, and which are suitable for intravenous administration. Preferably, solution formulations comprise (a) bendamustine, or pharmaceutically acceptable salts, solvates, or hydrates thereof, (b) at least one pharmaceutically acceptable non-aqueous solvent; (c) optionally, at least one pharmaceutically acceptable excipient, and (d) optionally, a pH adjuster, where the pharmaceutical composition is antioxidant-free, and formulated as a ready-to-dilute or ready-to-use liquid composition suitable for parenteral administration. The invention further relates to methods for manufacturing stable, antioxidant-free injectable solutions of bendamustine.
Inventor(s):	Harish Govindaraja Setty CHINNARI, Somashekhar BATTINI, Sumitra Ashokkumar PILLAI, Lourdu Chinnu Thippabattuni, BALASUBRAMANIAN Satheesh
Assignee:	Azurity Pharmaceuticals Inc
Application Number:	US18/328,392
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,844,784
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,844,784

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	VIVIMUSTA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	212209-001	Dec 7, 2022		RX	Yes	Yes			Y